Clinical trials and real-world evidence have established the benefit of chimeric antigen receptor (CAR) T-cell therapy to reduce progression of hematologic malignancies and, in some settings, increase overall survival. However, recent studies have highlighted that patients in long-term remission remain at risk of morbidity and nonrelapse mortality, primarily because of infections and subsequent myeloid malignancies. In addition, these patients may also be survivors of chemotherapy, radiation, and/or stem-cell transplant, with broad survivorship needs. Here, we provide a roadmap for the care of patients in long-term remission after CAR-T-cell therapies and discuss avenues for future research.
Faramand et al. (Wed,) studied this question.